Additional Relevant Details Cardiome has signed an exclusive license agreement with an affiliate of Allergan plc that will result in the Cardiome Group commercializing XYDALBA (Dalbavancin) in France, the U.K., Germany, Belgium, Nordic nations, certain other European nations (not already partnered), various Middle Eastern nations and Canada. Cardiome will provide Allergan with a staggered upfront payment totalling US$13 million and will provide Allergan additional milestone payments and royalties based upon commercial achievements and sales of XYDALBA. Additional terms of the agreement were not disclosed.